Cystic Fibrosis Trial, Recruiting NCT06487273 Sponsor: Physio-Assist Condition: Cystic Fibrosis
Back to Cystic Fibrosis

Cystic Fibrosis Trial, Recruiting

NCT06487273
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older (male or female)
  • People with a confirmed diagnosis of bronchiectasis (not caused by cystic fibrosis), confirmed by a CT scan
  • People who regularly and consistently produce mucus/phlegm
  • People whose condition is currently stable — meaning at least 4 weeks have passed since their last lung flare-up, and no changes have been made to their main treatments in the past 4 weeks
  • People who have had at least two lung flare-ups in the past 12 months that required a change in treatment, OR at least one lung flare-up in the past 12 months that required a hospital stay
  • People whom the trial doctor considers physically and mentally able to use the study device and follow the study procedures
  • People covered by a social security or health insurance system (where this applies in the relevant country)

Who may not be able to join:

  • People who are currently using certain powered airway clearance devices at home, such as SIMEOX, a high-frequency chest wall oscillation vest (e.g. The Vest), or intrapulmonary percussion ventilation (IPV)
  • People who have been using a powered mechanical cough assistance device at home for less than one year (such as the Cough Assist or Alpha300)
  • People who have cystic fibrosis
  • People whose main lung diagnosis is COPD, asthma, or certain other specific lung conditions (including active allergic bronchopulmonary aspergillosis, sarcoidosis, or bronchiectasis caused by a blockage or scarring in the airways)
  • People who currently smoke
  • People with a suspected but undiagnosed immune deficiency, or an unstable immune deficiency (confirm with trial site)
  • People on long-term treatments that suppress the immune system, if there is a risk those treatments may need to be stopped during the study
  • People with unstable heart conditions, such as a recent heart attack, unstable chest pain, uncontrolled heart rhythm problems, or unstable heart failure
  • People with unstable blood pressure or circulation problems
  • People with uncontrolled acid reflux that continues despite treatment (confirm with trial site)
  • People with a current collapsed lung (pneumothorax) or a high risk of developing one
  • People who are unable to cough strongly on their own (confirm with trial site)
  • People who had a significant episode of coughing up blood in the 6 weeks before joining the trial (confirm with trial site)
  • People who use a breathing tube, tracheostomy tube, or a breathing mask for more than 16 hours a day
  • People with a neuromuscular disease that affects breathing muscle strength (confirm with trial site)
  • People who have had chest or throat surgery, including oesophageal surgery, within the 3 months before joining
  • People who have had a severe acute lung injury or barotrauma (pressure-related lung injury) within the 3 months before joining
  • People who have difficulty clearing mucus from the upper airways due to muscle weakness in the throat, mouth, or breathing muscles (confirm with trial site)
  • People at risk of inhaling food or liquid into the airways, for example due to tube feeding or eating a recent meal close to device use (confirm with trial site)
  • People with breathing muscle weakness that makes it hard to tolerate extra breathing effort (confirm with trial site)
  • People with severely reduced lung volume (total lung capacity below 60% on full lung function testing)
  • People with large air pockets in the lungs (bullous emphysema)
  • People who are currently taking part in another interventional clinical trial, or who did so in the month before joining
  • People who are likely to move to an area not covered by this trial before completing their participation
  • Women who are pregnant, breastfeeding, or planning to become pregnant during the study — pregnancy is checked by a urine or blood test for women of childbearing age who are not using contraception
  • People who are subject to a court or administrative order restricting their freedom
  • People who are under a legal protection order

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sylvie Leroy, MD, Centre Hospitalier Universitaire de Nice

Phone: +33 7 63 23 66 15

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Physio-Assist
Registry
ClinicalTrials.gov
Start date
3 February 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇫🇷 France 🇩🇪 Germany 🇵🇱 Poland 🇵🇹 Portugal Reunion 🇬🇧 United Kingdom

Primary endpoints

Quality of life SGRQ at 6 months; The annual rate of pulmonary exacerbations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov